Subproject for Sorafenib for Hepatopulmonary Syndrome

This study is being conducted to determine whether sorafenib may be effective at treating hepatopulmonary syndrome (HPS) compared to placebo. Primary Aim: 1. To determine whether sorafenib affects alveolar-arterial oxygen gradient (AaPO2) at 12 weeks in patients with HPS Secondary Aims: 2. To determine whether sorafenib affects intrapulmonary shunting at 12 weeks 3. To determine whether sorafenib affects hematopoietic progenitor cell (HPC) and other biomarker levels at 8 and 12 weeks 4. To determine whether sorafenib affects SF-36 questionnaire scores and Mahler dyspnea index at 8 and 12 weeks 5. To determine whether sorafenib affects the distance walked in six minutes at 8 and 12 weeks 6. To determine whether sorafenib affects AaPO2 and PaO2 at 8 and 12 weeks in patients with HPS 7. To determine whether sorafenib affects oxygen saturation from pulse oximetry at 8 and 12 weeks in patients with HPS 8. To determine whether sorafenib affects functional class at 8 and 12 weeks 9. To determine the safety and side effects associated with sorafenib administration in patients with HPS